Cytran Names Bill Milligan President and COO.Business Editors, Health/Medical Writers KIRKLAND, Wash.--(BW HealthWire)--Dec. 5, 2000 Cytran, a privately held biotechnology company developing novel anti-cancer therapies, announced today the appointment of William D. Milligan as President and COO. Milligan has over 18 years' experience in the pharmaceutical and biotechnology industries, most recently serving as CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and on the Board of Directors of Intellivax International, Inc. of Montreal Of Montreal is an American indie pop band formed in Athens, Georgia, fronted by Kevin Barnes. It was among the second wave of groups to emerge from The Elephant 6 Recording Company. and Baltimore, a privately held company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. developing vaccines for influenza, HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. and other infectious diseases infectious diseases: see communicable diseases. . Prior to Intellivax, Milligan was employed by Hoffmann-La Roche Ltd (Canada) for eight years and played key roles in the integration of Syntex, Genentech Canada and Boehringer Mannheim following the acquisition of each by Roche. He served as Vice President in three separate business areas of Roche: the Biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. Division, Pharmaceutical Sales Division and Business Development and New Product Planning. From 1982 until 1990, Milligan was employed by Eli Lilly Canada, Inc. Toronto, holding various positions in marketing, sales and human resources. "Mr. Milligan brings broad experience and a strong track record of success in new product development, licensing and strategic alliances that will be of critical value as we prepare for commercialization of our lead drug candidate," said Dennis C. Fill, Chairman and CEO. "I also want to pay high tribute to Gene Larson for his major contributions as President and COO over the past 18 months and in helping to recruit an executive of Bill's caliber to succeed him. Gene will continue to help guide the Company as a Cytran boardmember." Milligan was a founding director of Comprehensive Care, Inc. and serves on the Board of Directors of Pheremone Sciences Corporation, Toronto. He completed a B.Sc. and graduate studies in Biochemistry at the University of Calgary. Cytran recently announced the closing of a $17 million private placement of convertible debentures with ALZA Corporation and Stephens Group, Inc. as lead investors. The funds will be used to support Phase II and III trials for its lead drug, IM862, as well as to advance preclinical development of other compounds in the Company's portfolio. Cytran, Inc., headquartered near Seattle, is a privately held biopharmaceutical company, developing and commercializing drugs that fight cancer through stimulating immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. response and inhibiting angiogenesis angiogenesis /an·gio·gen·e·sis/ (-jen´e-sis) vasculogenesis; development of blood vessels either in the embryo or in the form of neovascularization or revascularization. an·gi·o·gen·e·sis n. . For further information on the Company and its clinical trials, visit www.cytran.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion